MTOR and neoplasm: Although the predictive clinical value of these biomarkers is limited as cytotoxic chemotherapy is not routinely used to treat HCC, and the mTOR inhibitor everolimus was not active in a phase III trial [19], the different expression patterns nevertheless support the hypothesis that there may be age-specific and tumor site-specific molecular differences in HCC.